Pembrolizumab: Comparison Between Fixed Dose and Weight-Based Dose in the Treatment of Non-Small Cell Lung Cancer
Proceedings of Research and Practice in Allied and Environmental Health · 28.08.2026
DOI: 10.26537/prpaeh.v3i2.6127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of Research and Practice in Allied and Environmental Health, erschienen am 28.08.2026. Verfasst von Andreia Zuckschwerdt und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and is often associated with risk factors such as smoking, exposure to carcinogens, and genetic predisposition. Immunotherapy, particularly Pembrolizumab, has revolutionized NSCLC treatment by enhancing the immune response against tumor cells (1–3). The doses to be administered during treatment can be fixed doses or doses based on the patient's weight (4).
Objective
To compare the efficacy and costs associated with fixed-dose (FD) versus weight-based dosing (WBD) of Pembrolizumab in NSCLC treatment.
Methods
A literature review was conducted using PubMed and Elsevier databases, analyzing clinical and economic studies focusing on efficacy, safety, and cost of fixed-dose versus weight-based dosing regimens. Additionally, annual Pembrolizumab consumption at the Unidade Local de Saúde do Algarve (ULSALG) between October 2023 and October 2024 was evaluated, considering associated costs and simulating potential expenses with a WBD regimen, since the current regimen is a fixed dose.
Results
We analyzed 6 original studies focused on clinical efficacy, safety and costs associated with the two posological regimens of Pembrolizumab. Both regimens showed similar efficacy and safety profiles. but highlight economic advantages associated with WBD, especially in patients outside the standard weight range (50-100 kg). The FD regimen, on the other hand, simplifies logistics and minimizes dosage errors, making it widely adopted. Hospital data from ULSALG indicated a higher resource utilization with the fixed-dose regimen. When simulating weight-based dosing based on an average weight of 70 kg, the analysis suggested a reduction in resource consumption. The economic analysis at ULSALG demonstrates significant cost savings with WBD. Additionally, strategies such as vial sharing could further enhance economic efficiency.
Conclusion
The choice between FD and WBD requires careful consideration of patient characteristics and the administration context. Future studies should further explore the large-scale implementation impact of weight-based dosing.
Schlagwörter
Zitieren
APA
Zuckschwerdt, A., França, P., & Nascimento, T. (2026). Pembrolizumab: Comparison Between Fixed Dose and Weight-Based Dose in the Treatment of Non-Small Cell Lung Cancer. Proceedings of Research and Practice in Allied and Environmental Health. https://doi.org/10.26537/prpaeh.v3i2.6127
Vancouver
Zuckschwerdt A, França P, Nascimento T. Pembrolizumab: Comparison Between Fixed Dose and Weight-Based Dose in the Treatment of Non-Small Cell Lung Cancer. Proceedings of Research and Practice in Allied and Environmental Health. 2026. doi:10.26537/prpaeh.v3i2.6127
BibTeX
@article{Zuckschwerdt2026,
author = {Zuckschwerdt, Andreia and França, Pedro and Nascimento, Tânia},
title = {Pembrolizumab: Comparison Between Fixed Dose and Weight-Based Dose in the Treatment of Non-Small Cell Lung Cancer},
journal = {Proceedings of Research and Practice in Allied and Environmental Health},
year = {2026},
doi = {10.26537/prpaeh.v3i2.6127}
}
EUVIMED